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Abstract
Clinicians are well aware of existing pharmacologically-induced immune deficient status in kidney-transplanted patients
that will favor their susceptibility to bacterial or viral infections. Previous studies indicated that advanced Stage 4–5 Chronic
Kidney Disease might also be regarded as an immune deficiency-like status as well, even though the mechanisms are not
fully understood. Here, we analyzed the ex vivo frequency and the functional properties of both conventional and innate-
like T (ILT) lymphocyte subsets in the peripheral blood of 35 patients on hemodialysis, 29 kidney transplanted patients and
38 healthy donors. We found that peripheral blood cell count of ILT cells, as iNKT (invariant Natural Killer T) and MAIT
(mucosal-associated invariant T), were significantly decreased in hemodialyzed patients compared to healthy controls. This
deficiency was also observed regarding conventional T cells, including the IL-17-producing CD4+ Th17 cells. Pertaining to
regulatory T cells, we also noticed major modifications in the global frequency of CD4+CD25+Foxp3+ T lymphocytes,
including the resting suppressive CD45RA+Foxp3lo and activated suppressive CD45RA2Foxp3hi T cell subpopulations. We
found no significant differences between the immune status of hemodialyzed and kidney-transplanted subjects. In
conclusion, we demonstrated that both ILT and conventional T cell numbers are equally impaired in hemodialyzed and
kidney-transplanted patients.
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Introduction
Chronic kidney disease (CKD) is a common disease character-
ized by the progressive loss of the renal function that may lead to
the initiation of treatment by replacement therapy such as
hemodialysis or kidney transplantation (KT). Besides classical
complication of chronic renal failure such as hypertension, fluid
overload, hypocalcemia or even anemia, complications as a result
of infections, especially caused by bacteria, are also an important
source of morbidity and mortality in these patients, particularly at
the terminal stage (CKD-5) [1]. A possible explanation for this
susceptibility to infections is their frequent hospitalization, overuse
of antibiotics and other confounding factors like diabetes or auto-
immune related disease that are commonly associated with their
kidney disease. Therefore, compromised immune responses may also
explain this susceptibility to infectious agents [2]. Indeed, immuno-
logical abnormalities reported so far for CKD-5 patients include
reduced phagocytic functions, defective antigen presentation and
impaired B and T cell responses [3–8]. The mechanisms responsible
for these deficiencies are not fully elucidated.
T lymphocytes are currently considered as major players to
coordinate adaptive immune responses against infections. Recent-
ly, several studies highlighted the participation of a new group of T
cells, called innate-like T (ILT) cells, which are on the frontier
between innate and adaptive immune responses. Here, we focused
our attention on two ILT populations, namely invariant Natural
Killer T (iNKT) and mucosal-associated invariant T (MAIT) cells
that display conserved significant homologies between mouse and
human [9,10,11]. These lymphocytes produce a broad range of
cytokines few minutes after stimulation allowing them to modulate
both innate and acquired immunity in a large spectrum of
inflammatory diseases [9,10,11,12]. They express a highly
restricted T cell receptor (TCR) repertoire composed in humans
of a single invariant Va24Ja18 and Va7.2Ja33 for iNKT and
MAIT cells, respectively. In contrast to conventional T cells that
recognize peptides, iNKT cells recognize glycolipids presented by
CD1d while MAIT cells are activated by vitamin B metabolites
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presented by the MHC-related protein 1 (MR1) molecules [13,14].
Both iNKT and MAIT cells are generally regarded as protective
against infections and we reported that iNKT cells also attenuated
the development of anti-glomerular basement membrane glomer-
ulonephritis in a murine model [15,16,17,18]. Herein, we
analyzed the frequency of these innate-like T lymphocytes, namely
iNKT and MAIT cells, and of conventional T cells in the




Patient demographic characteristics and most relevant clinical
data are shown in Table 1. All patients entered in this study after
providing their informed consent. The study was conducted
according to the procedures of the Declaration of Helsinki and to
local ethic committee rules (Commission de Protection des
Personnes, Ile de France). Patient’s anonymity was protected.
Thirty-seven HD patients, 31 kidney transplanted patients and 38
healthy volunteer’s donors, considered here as controls, (Table 1)
(obtained after signed informed consent managed by the French
Blood Department) participated in the study.
Cell preparation
Blood samples were obtained from CKD or kidney transplanted
patients (End Stage Renal Disease) from Tenon Hospital (Kidney
Emergencies and Renal Transplantation and nephrology and
hemodialysis units), Paris, France. All analyses were performed on
freshly isolated peripheral blood mononuclear cells (PBMC) from
10 to 20 mL of blood by density-gradient centrifugation (Ficoll-
Paque PLUS; GE Healthcare). Cell-surface staining was per-
formed in PBS buffer containing 2% FCS and 0.01% NaN3 on ice,
as previously described [12,19]. Cells were first stained with
PBS57-loaded or empty-CD1d-tetramers (National Institutes of
Health Tetramer Core Facility), then with the following directly




Age (yr; mean 6 SEM) 40.461.74
Gender (female/male) 13/22
Cause of ESRD:
Vascular nephropathy (hypertensive sclerosis, thrombotic microangiopathy) 8
Autoimmune related nephropathy (systemic lupus erythematosus, Wegener granulomatosis, rheumatoid purpura, idiopathic GEM) 8
Primary glomerulonephritis (focal segmental glomerulosclerosis, IgA nephropathy, Alport syndrome) 7
Secondary glomerulonephritis (diabetes mellitus, type 1 diabetes, sickle cell disease) 5
Tubulointerstitial nephritis (reflux nephropathy, myeloma) 4
Congenital/hereditary nephropathy (polycystic kidney) 4
Unknown 1
Blood lymphocyte counts per mm3 (mean 6 SEM) 13356187
Transplanted patient
N 29
Age (yr; mean 6 SEM) 40.161.83
Gender (female/male) 10/19
Years post-transplantation (mean 6 SEM) 3.3460.59
Cause of ESRD:
Primary glomerulonephritis (Alport syndrome, IgA nephropathy, focal segmental glomerulosclerosis) 7
Congenital/hereditary nephropathy (polycystic kidney, Fabry disease, tuberous sclerosis, Bor syndrome) 6
Unknown 6
Tubulointerstitial nephritis (reflux nephropathy) 5
Vascular nephropathy (hypertensive sclerosis, atypical hemolytic uremic syndrome) 4
Autoimmune related nephropathy (systemic lupus erythematosus) 1
Blood lymphocyte counts per mm3 (mean 6 SEM) 13166147
MDRD (mL/min; mean 6 SEM) 61.964.03
Healthy donors
N 38
Age (yr; mean 6 SEM) 30.762.2
Gender (female/male) 15/23
Blood lymphocyte counts per mm3 (mean 6 SEM) 17946213
Two hemodialysed patients had glomerulonephritis and vascular nephropathy at the same time.
doi:10.1371/journal.pone.0105422.t001
Human T Cells and CKD Status
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conjugated monoclonal antibodies (eBioscience): anti-CD3, anti-
CD4, anti-CD8, anti-CD25, anti-CD45RA, anti-CD161, anti-
TCRVa7.2 and/or anti-Foxp3. Intra-cellular analysis of Foxp3
was performed after fixation and permeabilization using Foxp3
staining buffers (eBioscience). Data were acquired on a FACS-
Canto II flow cytometer (BD Biosciences) with the use of
FACSDiva Version 6.1.3 software (BD Biosciences) and were
analyzed with the FlowJo Version 8.5.3 software (TreeStar).
Lymphocyte subpopulations were analyzed within the lymphocyte
gate on forward and side-scatter plots. Results were expressed in
absolute numbers per mm3 of peripheral blood.
Intracellular cytokine staining
For intracellular cytokine staining, PBMCwere incubated for five
hours with PMA (25 ng/mL), Ionomycin (1 mg/mL) and Brefeldin
A (10 mg/mL, all from Sigma-Aldrich). Cells were stained with
CD1d-tetramer, washed and fixed with 4% paraformaldehyde and
permeabilized with 0.5% saponin (Sigma-Aldrich) before further
incubated with anti-CD3, anti-CD4, anti-CD8, anti-IL-4, anti-
IFNc anti-IL-17 antibodies. Isotype-matched antibodies were used
to define marker settings for cytokines antibodies.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
(version 6.0 for Mac OS X, San Diego, California USA). Groups
were compared using the nonparametric Mann-Whitney U test for
non-normally distributed variables. All p values were two-tailed,
and the statistical significance level was defined as a p,0.05.
Results and Discussion
Clinical data are presented at Table 1. In sum, of the 35 HD
patients, 13 were female and 22 male, with an age of 40.461.6
(range 19-59) years at the time of blood collection. The gender and
age of healthy donors were 15 females/23 males, 30.762.2 years
old (range 20–64). The cause of ESRD (End Stage Renal Disease)
for these HD patients was vascular nephropathy (8 patients),
autoimmune related nephropathy (8 patients), primary glomeru-
Figure 1. iNKT cell deficit in HD patients. (A) iNKT cells were double stained by anti-CD3 and the PBS57-loaded CD1d-tetramer. Representative
FACS profile showing the percentage of iNKT and MAIT cells in control versus HD patients. (B and C) HD patients had significant low numbers (B) and
percentage (C) of peripheral blood iNKT and MAIT cells when compared to healthy donors. Bars represent the median. (D) The frequency of CD4+ and
CD82 subsets respectively among gated iNKT and MAIT cells in control versus HD patients is represented. (E) The percentage of IL-4+ or IFNc+ cells
among gated iNKT lymphocytes was assessed after 5 h stimulation with PMA and ionomycin. Box-and-whisker plots are used to represent the
distributions. The bottom and the top of a box represent the 5th and 95th percentiles, and the bar in the box shows the median. **, P,0.001; ***, P,
0.0005; ****, P,0.0001 versus controls.
doi:10.1371/journal.pone.0105422.g001
Human T Cells and CKD Status
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lonephritis (7 patients), secondary glomerulonephritis (5 patients),
tubulointerstitial nephritis (4 patients), congenital/hereditary
nephropathy (4 patients) or unknown (1 patient). Two HD
patients had both glomerulonephritis and vascular nephropathy.
Eleven HD patients received corticoids associated or not with
immunossuppressive drugs (calcineurin inhibitors or selective
inhibitors of inosine monophosphate dehydrogenase or antime-
tabolite-drug). All analysis performed in our study were made
including or not these patients. Statistic differences reported below
were obtained whatever immunosuppressed patients were exclud-
ed or not (data not shown). For this reason, they were maintained
in the study.
Among the 31 kidney-transplanted patients, 11 were female and
20 male, with an age of 39.761.7 (range 20–59) years at the time
of blood collection. Patients were analyzed about 3.3460.59 years
post-transplantation. The cause of ESRD for these KD patients
was primary glomerulonephritis (7 patients), congenital/hereditary
nephropathy (6 patients), unknown (6 patient), tubulointerstitial
nephritis (5 patients), vascular nephropathy (4 patients), autoim-
mune related nephropathy (2 patients) or secondary glomerulo-
nephritis (1 patient). Their MDRD was 62.163.78 mL/min.
Herein, we analyzed the frequency of iNKT and MAIT cells in
the peripheral blood of CKD-5/Hemodialyzed (HD) patients.
iNKT cells were identified by CD1d/PBS57 tetramers and MAIT
Figure 2. CD4+ and CD8+ T cell numbers are reduced in HD patients. (A) CD4+ and CD8+T cell numbers are significant decreased in the
peripheral blood of HD patients compared to healthy donors. Bars represent the median. (B) The percentage of IFNc+ cells among gated CD8+ or
CD4+ T lymphocytes or (C) the percentage of IL-4+ and IL-17+ cells among gated CD4+ T lymphocytes was assessed after 6 h stimulation with PMA
and ionomycin. Box-and-whisker plots are used to represent the distributions. The bottom and the top of a box represent the 5th and 95th
percentiles, and the bar in the box shows the median. *, P,0.01; **, P,0.001; ***, P,0.0005 versus controls. Representative FACS analysis of IL-4, IL-
17 and IFNc production by gated CD4+ (E) or CD8+ (F) T cells from health donor controls (top) or HD patients (bottom) are represented.
doi:10.1371/journal.pone.0105422.g002
Human T Cells and CKD Status
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e105422
cells by the expression of CD3, CD161 and TCR Va7.2 chain
(Figure 1A). We found that the absolute number of iNKT and
MAIT cells was drastically reduced in HD patients compared to
control healthy donors (Figure 1B). We confirmed previous reports
showing that the number of total CD3+ T cells was diminished in
these patients (808.26130/mm3 in HD patients versus
12966156/mm3 in health donors) [20]. iNKT and MAIT cell
deficiency was also observed in terms of percentage among gated
CD3+ T cells (Figure 1C), thus confirming their pronounced
deficiency in HD patients. In addition, the subset distribution of
these particular T cell populations was also committed since we
found that the percentage of CD4+ and CD82 subsets were
enhanced among gated iNKT and MAIT cells, respectively
(Figure 1D) compared to controls. The reduced number of these
distinct iNKT or MAIT subsets limited a more accurate analysis of
their specific cytokine profile. However, ex vivo analysis of
cytokine-producing capacities did not outline significant differenc-
es in the percentage of IL-4+ or IFNc+ among gated iNKT cells
Figure 3. Global Foxp3+ T cell numbers are reduced in HD patients. (A) Representative FACS analysis of CD4+CD25+Foxp3+T cells and their
distinct subsets on PBMC from control (top) and HD patients (bottom). (B) CD4+CD25+Foxp3+T cell numbers are reduced in HD patients. (C to E)
Among these gated cells, cytokine-secreting CD45RA2Foxp3lo nonsuppressive (C), resting suppressive CD45RA+Foxp3lo (D) and activated suppressive
CD45RA2Foxp3hi (E) cells, all these subsets are reduced in HD patients compared to controls. Bars represent the median. *, P,0.01; ****, P,0.0001.
doi:10.1371/journal.pone.0105422.g003
Table 2. Numbers of distinct T cell populations in the peripheral blood of kidney-transplanted versus healthy donors.
T cell populations Number per mm3 in p
transplanted patients healthy donors
iNKT 0.7660.15 2.3160.78 0.0360
MAIT 3.7861.28 44.7668.50 0.0107
CD4 501.4670.4 765.7685.1 0.0098
CD8 365.3651.7 407.0653.9 0.4875
CD4+Foxp3+CD25+ 22.4664.87 51.8166.43 0.0005
CD45RA-Foxp3lo 16.2663.45 25.9463.31 0.0394
CD45RA+Foxp3lo 7.1261.65 15.7862.27 0.0036
CD45RA-Foxp3hi 4.2060.90 9.7161.36 0.0017
Results are expressed as mean 6 SEM of cell counts in the peripheral blood of kidney-transplanted versus healthy donors. Mann Whitney test was used to compare the
sample.
p,0.05 are considered as significant.
doi:10.1371/journal.pone.0105422.t002
Human T Cells and CKD Status
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Figure 4. Both ILT and conventional T cells are equally deficient in HD and KD patients. (A) HD patients had no significant differences in
their number of iNKT, MAIT, CD4+ and CD8+ T cells when compared to kidney transplanted (KT) patients. Bars represent the median. (B)
CD4+CD25+Foxp3+T cell numbers are similarly reduced in HD as in KD patients. Among these gated cells, cytokine-secreting CD45RA2Foxp3lo
nonsuppressive, resting suppressive CD45RA+Foxp3lo and activated suppressive CD45RA2Foxp3hi cell levels, are also similar in HD and KD patients. (C
and D) The percentage of IFNc+, IL-4+ or IL-17+ cells among gated CD4+ (C) or CD8+ (D) T lymphocytes was assessed after 6 h stimulation with PMA
and ionomycin. Box-and-whisker plots are used to represent the distributions. The bottom and the top of a box represent the 5th and 95th
percentiles, and the bar in the box shows the median. (A and B) Bars represent the median. *, P,0.01.
doi:10.1371/journal.pone.0105422.g004
Human T Cells and CKD Status
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e105422
between patients and healthy controls (Figure 1E) indicating that
these cells are functional, but yet in very few numbers in HD
patients.
Deficiency in peripheral blood cell count and percentage was
also observed in HD patients concerning CD4+ and CD8+ T cells
(Figure 2A). Using a short, 6 hours, polyclonal stimulation, we
found no significant difference in the ability of ex vivo CD4+ T
cells to secrete IFNc (Figure 2B and 2E). Similarly, the percentage
of IFNc-producing CD8+ T cells was unchanged in HD patients
compared to controls (Figure 2B and 2F). This was also true
regarding IL-4-producing CD4+ (Figure 2C and 2E) or CD8+ T
cells (Figure 2C and 2F). Conversely, the frequency of IL-17A (or
IL-17)-producing CD4+ T cells was significantly reduced in HD
patients (Figure 2D and 2E). No significant difference was
observed concerning the ability of CD8+ T cells from HD
patients to secrete IL-17 (Figure 2D and 2F). IL-17-producing
Th17 CD4+ T cells are usually considered as playing an important
role against infections including fungal infections [21]. Polymor-
phisms within the IL-17E and IL-17RA genes are associated with
end stage renal disease [22], suggesting that IL-17 family or its
receptors could influence the severity of the kidney inflammatory
response. Together, our findings reveal that CD4+ T cells in HD
patients are impaired in number with a pronounced deficiency in
their IL-17-producing subset, namely CD4+ Th17 cells.
In addition to the analysis of ex vivo cytokine-producing
capacities, we also focused our attention on regulatory
Foxp3+CD4+ T (Treg) cells that play a key role in the regulation
of inflammatory responses. Treg cells are usually designed as
CD25highFoxp3+ cells. We found that HD patients presented a
global deficiency in the CD4+Foxp3+CD25+ T cells count
(Figure 3A and 3B). Previous reports have highlighted that TCR
activated human T cells can express Foxp3 and CD25 but these
cells are not suppressive [23,24]. To address this issue, new
combinations of markers are now used to distinguish suppressive
from nonsuppressive Foxp3+ T cells. A pertinent example is the
analysis of CD45RA expression associated with distinct levels of
Foxp3 [25] (Figure 3A). This approach revealed that the
peripheral number of cytokine-secreting CD45RA2Foxp3lo non-
suppressive (Figure 3C), resting suppressive CD45RA+Foxp3lo
(Figure 3D) and activated suppressive CD45RA2Foxp3hi (Fig-
ure 3E) T cell subpopulation were significantly reduced in HD
patients compared to controls. Globally these findings endorse the
above results showing that the immune system of HD patients is
dysregulated not only at the level of non conventional ILT iNKT
and MAIT cells but also of conventional effector and regulatory T
cells. This global immune dysregulation might favor the suscep-
tibility of these patients to infections.
These results aimed us to ask a key question: are these immune
deficits observed in HD patients similar to those reported in
kidney-transplanted persons? Kidney transplantation is a common
treatment for HD patients. We confirmed an immune deficit in
kidney-transplanted patients in terms of T cell counts when
compared to healthy donors (Table 2). Interestingly, the analysis
of kidney-transplanted patients clearly shows that their immune
system is equally impaired as those from ERDS patients since we
found no significant difference between the distinct ILT and
conventional T cell populations tested (Figure 4). Indeed, the
number of peripheral blood iNKT, MAIT, CD4+, CD8+ and
CD4+CD25+Foxp3+ T cell populations, including CD45RA2Fox-
p3lo nonsuppressive, resting suppressive CD45RA+Foxp3lo T cell
and activated suppressive CD45RA2Foxp3hi T cell subpopula-
tions were similar in kidney transplanted and HD patients
(Figure 4A and 4B). Concerning their cytokine profile, the
frequency of CD4- or CD8-producing IFNc or IL-4 was similar
between HD and KT patients (Figure 4C and 4D). IL-17-
producing T cells was slightly different since the percentage of
IL-17+ among gated CD4s T cells was enhanced in KT compared
to HD patients (Figure 4C). However, this was not confirmed in
terms of total cell counts of IL-17-producing CD4+ T cells
(5.962.6 versus 4.361.26103/ml for HD versus KT patients,
respectively).
Overall, our findings clearly show that HD patients presented
similar immune dysfunctions as transplanted patients. This
information is of high clinical value, because clinicians are well
aware of the poor immunological status of transplanted patients
but underestimate the immunological status of HD patient per se.
Furthermore, our findings concerning ILT cells, namely MAIT
and iNKT cells, are the first evidence that these lymphocytes are
reduced in the peripheral blood of HD and kidney-transplanted
patients. Their deficiency likely favors the susceptibility of these
patients to infections. T cell counts were also reduced in terms of
conventional T cell subsets namely CD8+, CD4+, Th17,
CD4+CD25+Foxp3+ and their subsets: nonsuppressive
CD45RA2Foxp3lo, resting suppressive CD45RA+Foxp3lo T cell
and activated suppressive CD45RA2Foxp3hi T cell subpopula-
tions. The low number of resting suppressive CD45RA+Foxp3lo
and activated suppressive CD45RA2Foxp3hi T cell subsets, could
contribute to the global dysregulation of the immune systems
observed so far in CKD and transplanted patients.
In conclusion, kidney failure results in a global T cells immune
dysfunction that can contribute to enhance the risk of complica-
tions due to infections in particular. Our, data reinforce the
underestimated immune dysfunction found in HD patients, which
appears similar to kidney-transplanted patients. Overall our
findings emphasize the importance of tight clinical fellow-up of
hemodialyzed patients, especially in an infectious context.
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